3 Drug Stocks to Buy at a Discount
The pharmaceutical industry is highly technical, and significant developments can rapidly transform the sector. For instance, Novo Nordisk's (NYSE: NVO) introduction of GLP-1 weight loss drugs was a huge development. Eli Lilly (NYSE: LLY) introduced more attractive GLP-1 drugs, however, leading to Novo Nordisk losing its early lead in the weight loss niche.
More change is on the way, including from Novo Nordisk, but if you have a contrarian bent, you might prefer out-of-favor drug makers Bristol Myers Squibb (NYSE: BMY), (NYSE: MRK), and (NYSE: PFE).
Novo Nordisk kick-started the GLP-1 market in a big way. Eli Lilly entered the market with GLP-1 shots that were more attractive. This illustrates how rapidly the pharmaceutical sector can evolve. But the change isn't over yet, with Novo Nordisk just receiving approval to sell a GLP-1 pill.
Source Fool.com
Pfizer Inc. Stock
With 14 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 27 € there is a positive potential of 24.05% for Pfizer Inc. compared to the current price of 21.77 €.
